The State University of New York has presented new antibody-drug conjugates (ADCs) consisting of trastuzumab antibody targeting human epidermal growth factor receptor 2 (HER2) covalently linked to Toll-like receptor 7 (TLR7) and/or TLR8 agonists through a linker reported to be useful for the treatment of cancer and infections.
Hillstream Biopharma Inc. has described new salinomycin derivatives acting as angiogenesis inhibitors reported to be useful for the treatment of cancer.
The University of Antwerp has identified new quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one HER4 (ERBB4) inhibitors reported to be useful for the treatment of heart failure, cancer, fibrosis, and metabolic and inflammatory disorders.
Genfleet Therapeutics (Shanghai) Inc. has synthesized new mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Convalife (Shanghai) Health Technology Co. Ltd. has presented new thyroid hormone receptor α (TR-α) and (TR-β) agonists reported to be useful for the treatment of nonalcoholic fatty liver disease, obesity, liver fibrosis, type 2 diabetes and hypercholesterolemia.
Janssen Pharmaceutica NV has described 4-amino-6-oxo-pyridazine derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, asthma and metabolic, autoimmune, liver, renal, cardiovascular and inflammatory disorders, among other disorders.
Mindset Pharma Inc. has patented indole derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of neurological disorders and psychosis, among other disorders.
RSS